Ambeed.cn

首页 / / / / AD80

AD80 {[allProObj[0].p_purity_real_show]}

货号:A712840

AD80 is a multikinase inhibitor with inhibitions on RET, RAF, SRC and S6K.

AD80 化学结构 CAS号:1384071-99-1
AD80 化学结构
CAS号:1384071-99-1
AD80 3D分子结构
CAS号:1384071-99-1
AD80 化学结构 CAS号:1384071-99-1
AD80 3D分子结构 CAS号:1384071-99-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

AD80 纯度/质量文件 产品仅供科研

货号:A712840 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 c-RET 其他靶点 纯度
Regorafenib +++

RET, IC50: 1.5 nM

98%
TG101209 ++

RET, IC50: 17 nM

FLT3 99%+
Danusertib +

RET, IC50: 31 nM

99%+
AD80 ++++

RET V804M, IC50: 0.6 nM

RET wt, IC50: 1.3 nM

Src,Raf 99+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 A-raf B-Raf C-Raf/Raf-1 Raf 其他靶点 纯度
Encorafenib 99%+
GDC-0879 ++++

B-Raf, IC50: 0.13 nM

99%+
SB-590885 ++++

B-Raf, Ki: 0.16 nM

99%+
RAF265 99%+
Dabrafenib ++++

B-Raf, IC50: 5.2 nM

B-Raf (V600E), IC50: 0.7 nM

+++

C-Raf, IC50: 6.3 nM

98%
Lifirafenib ++++

WT A-RAF, IC50: 1 nM

++

BRAF(V600E), IC50: 23 nM

BRAF WT, IC50: 32 nM

+++

C-RAF (Y340/341D), IC50: 7 nM

EGFR 98%
ZM 336372 +

C-Raf, IC50: 70 nM

99%+
NVP-BHG 712 +

C-Raf, IC50: 0.395 μM

99%+
CCT196969 +

BRAF, IC50: 0.1 μM

++

CRAF, IC50: 0.01 μM

Src 98%
Vemurafenib ++

B-Raf, IC50: 100 nM

B-Raf (V600E), IC50: 31 nM

+

C-Raf, IC50: 48 nM

98+%
PLX4720 ++

B-Raf, IC50: 160 nM

B-Raf (V600E), IC50: 13 nM

+++

C-Raf-1 (Y340D/Y341D), IC50: 6.7 nM

BRK 99+%
GW 5074 +++

C-Raf, IC50: 9 nM

99%+
Avutometinib +++

BRAF V600E, IC50: 8.2 nM

BRAF, IC50: 19 nM

+

CRAF, IC50: 56 nM

98%
LY3009120 ++++

BRAF(V600E), IC50: 5.8 nM

BRAF WT, IC50: 15 nM

++++

C-Raf, IC50: 4.3 nM

99%+
Agerafenib ++

B-Raf (V600E), Kd: 14 nM

B-Raf, Kd: 36 nM

+

C-Raf, Kd: 39 nM

RET 99%+
TAK-632 +++

B-Raf, IC50: 8.3 nM

++++

C-Raf, IC50: 1.4 nM

99%+
AZ 628 +

B-Raf, IC50: 105 nM

B-Raf (V600E), IC50: 34 nM

++

C-Raf-1, IC50: 29 nM

99%
PLX7904 98+%
Sorafenib ++

B-Raf (V599E), IC50: 38 nM

B-Raf, IC50: 22 nM

++++

Raf-1, IC50: 6 nM

++++

Raf-1, IC50: 6 nM

99%
Tovorafenib 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

AD80 生物活性

靶点
  • c-RET

    RET V804M, IC50:0.6 nM

    RET wt, IC50:1.3 nM

描述 AD80 is a multikinase inhibitor targeting on RET, RAF, SRC and S6K, eliminated its binding with TOR. Oral administration of AD80 resulted in a notable 70–90% of animals developing to adulthood in our Drosophila ptc>dRetMEN2B model. It restored Src and Ras activities by the ectopic Src activation and thus strongly suppressed wing vein pattern phenotypes. AD80 inhibited proliferation of MZ-CRC-1 and TT thyroid cancer cells in culture, probably through the induction of apoptosis, with potent downregulation of phosphorylated Ret and several downstream biomarkers. AD80 also promoted enhanced tumour growth inhibition and reduced body-weight modulation relative to vandetanib in a mouse xenograft model. AD80 showed high activity in RET kinase gatekeeper mutant cells, Ba/F3 cells expressing KIF5B-RETV804M or CCDC6-RETV804M and inhibited phosphorylation of RET as well as of ERK, AKT, and S6K in these cells.
作用机制 AD80 specifically targets RET and tightly binds to RET fusion kinase, effectively inhibiting RET kinase in DFG-out conformation.[1]

AD80 动物研究

Dose Mice: 20 mg/kg[3] (i.p.); 30 mg/kg[1] (p.o.)
Administration i.p., p.o.

AD80 参考文献

[1]Dar AC, Das TK, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012 Jun 6;486(7401):80-4.

[2]Plenker D, Riedel M, et al. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci Transl Med. 2017 Jun 14;9(394). pii: eaah6144.

AD80 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.56mL

2.11mL

1.06mL

21.12mL

4.22mL

2.11mL

AD80 技术信息

CAS号1384071-99-1
分子式C22H19F4N7O
分子量 473.426
别名
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Room Temperature

溶解度

DMSO: 50 mg/mL(105.61 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+30% PEG300+water 0.5 mg/mL clear

PO 0.5% CMC-Na 45 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。